# Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

> **NCT07286292** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institut de Recherches Internationales Servier (I.R.I.S.)** · enrollment: 10 (estimated)

## Conditions studied

- Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

## Interventions

- **DRUG:** Vorasidenib

## Key facts

- **NCT ID:** NCT07286292
- **Lead sponsor:** Institut de Recherches Internationales Servier (I.R.I.S.)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-15
- **Primary completion:** 2033-05-02
- **Final completion:** 2033-05-02
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07286292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07286292, "Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07286292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*